Having identified microbiome and metabolome signatures that were upregulated or downregulated by L. reuteri in darkness rats, the next step was to assess the interplay across gut microbiota compositions, faecal metabolites, serum metabolites, and hepatic GALR1-mediated signaling pathway, in relation to the observed impact of L. reuteri regimen on dyslipidemia in darkness rats. The gene discussed is GALR1; the disease is metabolic syndrome.